Publications
6 found
Show per page
Brown, Jennifer Anne, Motaboli, Lipontso, Lerotholi, Malebanye, Kohler, Maurus, Haenggi, Kathrin, Mokete, Moliehi, Chakela, Makobefo Gladys, Kao, Mpho, Kopo, Mathebe, Mokebe, Moleboheng, BMJ Open, 15(2). https://doi.org/10.1136/bmjopen-2024-085404
, Nsakala, Bienvenu Lengo, Lukau, Blaise, Ayakaka, Irene, Amstutz, Alain, Ehmer, Jochen, Klicpera, Anna, Klimkait, Thomas, Glass, Tracy, et al. (2025). Cohort profile: the Viral load Cohort North-East Lesotho (VICONEL) from 2016 to 2023 – cohort description, test volumes, predictors of viraemia and the road ahead [Journal-article].
Brown, Jennifer Anne, Motaboli, Lipontso, Lerotholi, Malebanye, Kohler, Maurus, Haenggi, Kathrin, Mokete, Moliehi, Chakela, Makobefo Gladys, Kao, Mpho, Kopo, Mathebe, Mokebe, Moleboheng, BMJ Open, 15(2). https://doi.org/10.1136/bmjopen-2024-085404
, Nsakala, Bienvenu Lengo, Lukau, Blaise, Ayakaka, Irene, Amstutz, Alain, Ehmer, Jochen, Klicpera, Anna, Klimkait, Thomas, Glass, Tracy, et al. (2025). Cohort profile: the Viral load Cohort North-East Lesotho (VICONEL) from 2016 to 2023 – cohort description, test volumes, predictors of viraemia and the road ahead [Journal-article].
Hauser, David, Open Forum Infectious Diseases, 11(10). https://doi.org/10.1093/ofid/ofae527
, Lang, Christopher, Mittelholzer, Christian, Otte, Fabian, Kipfer, Enja, Zhang, Yuepeng, Lett, Martin, Schebitz, Christiane, Müller, Roman-Ulrich, Klimkait, Wilfried, & Klimkait, Thomas. (2024). Benefits of Repeated SARS-CoV-2 Vaccination and Virus-induced Cross-neutralization Potential in Immunocompromised Transplant Patients and Healthy Individuals [Journal-article].
Hauser, David, Open Forum Infectious Diseases, 11(10). https://doi.org/10.1093/ofid/ofae527
, Lang, Christopher, Mittelholzer, Christian, Otte, Fabian, Kipfer, Enja, Zhang, Yuepeng, Lett, Martin, Schebitz, Christiane, Müller, Roman-Ulrich, Klimkait, Wilfried, & Klimkait, Thomas. (2024). Benefits of Repeated SARS-CoV-2 Vaccination and Virus-induced Cross-neutralization Potential in Immunocompromised Transplant Patients and Healthy Individuals [Journal-article].
Kipfer, Enja Tatjana, Hauser, David, Lett, Martin J., Otte, Fabian, eLife, 12. https://doi.org/10.7554/eLife.89035
, Zhang, Yuepeng, Lang, Christopher M R, Chami, Mohamed, Mittelholzer, Christian, & Klimkait, Thomas. (2023). Rapid cloning-free mutagenesis of new SARS-CoV-2 variants using a novel reverse genetics platform.
Kipfer, Enja Tatjana, Hauser, David, Lett, Martin J., Otte, Fabian, eLife, 12. https://doi.org/10.7554/eLife.89035
, Zhang, Yuepeng, Lang, Christopher M R, Chami, Mohamed, Mittelholzer, Christian, & Klimkait, Thomas. (2023). Rapid cloning-free mutagenesis of new SARS-CoV-2 variants using a novel reverse genetics platform.
Kipfer, E. T., Hauser, D., Lett, M. J., Otte, F., Urda, L., Zhang, Y., Lang, C. M., Chami, M., Mittelholzer, C., & Klimkait, T. (2023). Rapid cloning-free mutagenesis of new SARS-CoV-2 variants using a novel reverse genetics platform [Journal-article]. eLife, 12. https://doi.org/10.7554/elife.89035.3
Kipfer, E. T., Hauser, D., Lett, M. J., Otte, F., Urda, L., Zhang, Y., Lang, C. M., Chami, M., Mittelholzer, C., & Klimkait, T. (2023). Rapid cloning-free mutagenesis of new SARS-CoV-2 variants using a novel reverse genetics platform [Journal-article]. eLife, 12. https://doi.org/10.7554/elife.89035.3
Seeburg, U., Urda, L., Otte, F., Lett, M. J., Caimi, S., Mittelholzer, C., & Klimkait, T. (2023). Virus Inactivation by Formaldehyde and Common Lysis Buffers. Viruses, 15(8). https://doi.org/10.3390/v15081693
Seeburg, U., Urda, L., Otte, F., Lett, M. J., Caimi, S., Mittelholzer, C., & Klimkait, T. (2023). Virus Inactivation by Formaldehyde and Common Lysis Buffers. Viruses, 15(8). https://doi.org/10.3390/v15081693
Brown, Jennifer A., Nsakala, Bienvenu L., Mokhele, Kuena, Rakuoane, Itumeleng, Muhairwe, Josephine, HIV medicine, 23(3), 287–293. https://doi.org/10.1111/hiv.13189
, Amstutz, Alain, Tschumi , Nadine, Klimkait, Thomas, & Labhardt, Niklaus D. (2022). Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: a prospective cohort study in Lesotho (DO-REAL study).
Brown, Jennifer A., Nsakala, Bienvenu L., Mokhele, Kuena, Rakuoane, Itumeleng, Muhairwe, Josephine, HIV medicine, 23(3), 287–293. https://doi.org/10.1111/hiv.13189
, Amstutz, Alain, Tschumi , Nadine, Klimkait, Thomas, & Labhardt, Niklaus D. (2022). Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: a prospective cohort study in Lesotho (DO-REAL study).